Obesity News

Injectable Wegovy 2.4 mg was associated with a 20% reduction in the risks for major adverse cardiovascular events among patients with overweight or obesity and established CVD, data show.

The Mayo Clinic was once again ranked the No. 1 hospital in the United States for diabetes and endocrinology by U.S. News & World Report, followed by NYU Langone Hospitals.

Compared with placebo, injectable semaglutide 2.4 mg reduced risk for major adverse CV events by 20% for people with overweight or obesity and established CVD, according to topline data from the SELECT study.

The AGA applauded the reintroduction of the Treat and Reduce Obesity Act into the 118th Congress as this bill would expand Medicare coverage for screening and treatment of obesity by health care providers specializing in obesity care.

A personal injury law firm has filed a lawsuit against Novo Nordisk and Eli Lilly, alleging the manufacturers “downplayed the severity of the gastrointestinal events caused by Ozempic and Mounjaro,” such as gastroparesis and gastroenteritis.

Two different trials showed that adults with obesity lost an average of 26% of their body weight with either intensive lifestyle intervention followed by 72 weeks of Mounjaro or 88 weeks of continuous Mounjaro use.

BOSTON — The phenomenon known as metabolic adaptation and its impact on weight regain remains “one of the biggest controversies in the nutrition field,” according to a presenter at NUTRITION.

BOSTON — Researchers have identified around 500 genes that directly influence the foods people eat.

BMI in the overweight range was not associated with an increased risk for all-cause mortality, highlighting the limitations of using BMI to predict mortality risk independent of other risk factors, researchers found.

Proteins and genetic material secreted by fatty liver cells stimulate the spread of colorectal cancer to the liver, study results published in Cell Metabolism showed.